The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.

Mathis S, Chapuis N, Borgeot J, Maynadié M, Fontenay M, Béné MC, Guy J, Bardet V. Cytometry B Clin Cytom. 2014 Nov 17. doi: 10.1002/cyto.b.21200. [Epub ahead of print] PMID: 25399680 [PubMed - as supplied by publisher]
Related Citations
READ MORE

Posted: December 19, 2014

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.

Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Keith Stewart A. Eur J Haematol. 2014 Nov 17. doi: 10.1111/ejh.12491. [Epub ahead of print] PMID: 25402977 [PubMed - as supplied by publisher]
Related Citations
READ MORE

Posted: December 19, 2014

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.

Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, Dimopoulos MA. Br J Haematol. 2014 Nov 18. doi: 10.1111/bjh.13227. [Epub ahead of print] PMID: 25403264 [PubMed - as supplied by publisher]
Related Citations
READ MORE

Posted: December 19, 2014

Page 82 of 87« First...102030...8081828384...Last »